Analyst Price Targets — ARGX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 31, 2026 11:33 am | — | Morgan Stanley | $1,250.00 | $1,023.21 | TheFly | Argenx price target raised to $1,250 from $1,230 at Morgan Stanley |
| August 26, 2026 10:46 am | Derek Archila | Wells Fargo | $1,415.00 | $1,019.49 | TheFly | Argenx price target raised to $1,415 from $1,350 at Wells Fargo |
| August 26, 2026 7:24 am | Xian Deng | UBS | $1,400.00 | $1,019.49 | StreetInsider | UBS Upgrades argenx SE (ARGX) to Buy |
| August 18, 2026 12:20 pm | — | Morgan Stanley | $1,230.00 | $989.79 | TheFly | Argenx price target raised to $1,230 from $1,200 at Morgan Stanley |
| August 18, 2026 11:49 am | — | Wedbush | $1,150.00 | $987.84 | TheFly | Argenx price target raised to $1,150 from $1,050 at Wedbush |
| August 18, 2026 11:44 am | — | Oppenheimer | $1,100.00 | $987.84 | TheFly | Argenx price target raised to $1,100 from $1,037 at Oppenheimer |
| August 18, 2026 11:33 am | Luca Issi | RBC Capital | $1,100.00 | $987.84 | StreetInsider | argenx SE (ARGX) PT Raised to $1,100 at RBC Capital, 'We Think Approval In DM Is When, Not If' |
| August 18, 2026 11:22 am | Danielle Brill | Truist Financial | $1,095.00 | $987.84 | TheFly | Argenx price target raised to $1,095 from $1,030 at Truist |
| August 18, 2026 10:07 am | — | H.C. Wainwright | $1,202.00 | $987.84 | TheFly | Argenx price target raised to $1,202 from $940 at H.C. Wainwright |
| August 17, 2026 11:01 am | — | Piper Sandler | $1,215.00 | $851.29 | TheFly | Argenx price target raised to $1,215 from $1,075 at Piper Sandler |
Latest News for ARGX
Argenx's top and bottom lines are growing robustly. The company expects to report multiple pivotal clinical results through the second half of 2027.
September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September:
Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx's immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced the successful completion of the acquisition of Forte Biosciences, Inc. (“Forte”) (Nasdaq: FBRX). The acquisition expands argenx's portfolio of differentiated immunology medicines,…
Wall Street analysts are reshuffling their bets ahead of a critical inflation report and NVIDIA earnings that could jolt markets in either direction. Find out which names got upgraded, cut, or newly covered before the opening bell Wednesday.
Argenx recently announced Phase 3 results for Vyvgart Hytrulo in treating autoimmune myositis. While there was one disappointment with the clinical study, the results were positive overall.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ARGX.
Senate Trading
No Senate trades found for ARGX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.